These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37218402)

  • 1. Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.
    Agin-Liebes J; Hickman RA; Vonsattel JP; Faust PL; Flowers X; Utkina Sosunova I; Ntiri J; Mayeux R; Surface M; Marder K; Fahn S; Przedborski S; Alcalay RN
    Mov Disord; 2023 Aug; 38(8):1541-1545. PubMed ID: 37218402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
    Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T
    Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
    Alcalay RN; Hsieh F; Tengstrand E; Padmanabhan S; Baptista M; Kehoe C; Narayan S; Boehme AK; Merchant K
    Mov Disord; 2020 Jan; 35(1):134-141. PubMed ID: 31505072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of p.G2019S Mutation in the
    Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
    J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-α Pathway.
    Lin CH; Lin HY; Ho EP; Ke YC; Cheng MF; Shiue CY; Wu CH; Liao PH; Hsu AY; Chu LA; Liu YD; Lin YH; Tai YC; Shun CT; Chiu HM; Wu MS
    Mov Disord; 2022 Apr; 37(4):745-757. PubMed ID: 34918781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology.
    Jackson LM; Woodruff BK; Tremblay C; Shill HA; Beach TG; Serrano GE; Adler CH
    Mov Disord Clin Pract; 2024 Jul; 11(7):874-878. PubMed ID: 38757351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
    Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS
    Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.
    Gatto EM; Parisi V; Converso DP; Poderoso JJ; Carreras MC; Martí-Massó JF; Paisán-Ruiz C
    Neurosci Lett; 2013 Mar; 537():1-5. PubMed ID: 23340200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.
    Silveira-Moriyama L; Guedes LC; Kingsbury A; Ayling H; Shaw K; Barbosa ER; Bonifati V; Quinn NP; Abou-Sleiman P; Wood NW; Petrie A; Sampaio C; Ferreira JJ; Holton J; Revesz T; Lees AJ
    Neurology; 2008 Sep; 71(13):1021-6. PubMed ID: 18809839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
    Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
    PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First Japanese autopsy case showing LRRK2 mutation G2019S and TDP-43 proteinopathy.
    Sakuwa M; Adachi T; Suzuki Y; Yoshida K; Fukuda H; Miura H; Adachi Y; Hanajima R
    Parkinsonism Relat Disord; 2021 Oct; 91():85-87. PubMed ID: 34543853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.